V souladu s legislativou České republiky poskytuje Společnost služby pouze kvalifikovaným investorům!

RxSight (RXST) FINANCIAL RESULTS FOR SECOND QUARTER 2022.

Start-ups and IPO

09.08.2022

Non-GAAP net loss per share for the second quarter of 2022 was -0.50 dollars.

Revenue was $11.4 million, up 132.7% from the same period last year.

Categories